Complement in typical hemolytic uremic syndrome

Seminars in Thrombosis and Hemostasis

Volumn 36, Issue 6, 2010, Pages 620-624

  Orth, Dorothea ^a   Würzner, Reinhard ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

complement; Hemolytic uremic syndrome; Shiga toxin

Indexed keywords

COMPLEMENT; VEROTOXIN 2; VIRULENCE FACTOR;

CELL SURFACE; COMPLEMENT ACTIVATION; COMPLEMENT DISORDER; COMPLEMENT SYSTEM; DIARRHEA; DISEASE ASSOCIATION; ENTEROHEMORRHAGIC ESCHERICHIA COLI; HEMOLYTIC UREMIC SYNDROME; HUMAN; KIDNEY FAILURE; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT FACTOR H; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HEMOLYTIC-UREMIC SYNDROME; HOST-PATHOGEN INTERACTIONS; HUMANS; KIDNEY; SHIGA TOXIN;

EID: 77957550498     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0030-1262883     Document Type: Review

References (24)

1. Karch H, Tarr P I., Bielaszewska M. Enterohaemorrhagic Escherichia coli in human medicine. Int J Med Microbiol 2005 295 (67) 405-418
2. Kavanagh D, Richards A, Atkinson J. Complement regulatory genes and hemolytic uremic syndromes. Annu Rev Med 2008 59 293-309
3. Orth D, Grif K, Khan A B., Naim A, Dierich M P., Würzner R. The Shiga toxin genotype rather than the amount of Shiga toxin or the cytotoxicity of Shiga toxin in vitro correlates with the appearance of the hemolytic uremic syndrome. Diagn Microbiol Infect Dis 2007 59 (3) 235-242
4. te Loo D M., Monnens L A., van Der Velden T J. et al. Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome. Blood 2000 95 (11) 3396-3402
5. Orth D, Grif K, Zimmerhackl L B., Würzner R. Prevention and treatment of enterohemorrhagic Escherichia coli infections in humans. Expert Rev Anti Infect Ther 2008 6 (1) 101-108
6. Loirat C, Noris M, Frémeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2008 23 (11) 1957-1972
7. Caprioli J, Remuzzi G. Complement hyperactivation may cause atypical haemolytic uraemic syndromegain-of-function mutations in factor B. Nephrol Dial Transplant 2007 22 (9) 2452-2454
8. Frémeaux-Bacchi V, Miller E C., Liszewski M K. et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 2008 112 (13) 4948-4952
9. Speth C, Würzner R, Stoiber H, Dierich M P. Complement In: Paul WE Fundamental Immunology. Philadelphia, PA Lippincott-Raven 2008 1047-1078
10. Würzner R. Evasion of pathogens by avoiding recognition or eradication by complement, in part via molecular mimicry. Mol Immunol 1999 36 (45) 249-260
11. Orth D, Khan A B., Naim A et al. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol 2009 182 (10) 6394-6400
12. Monnens L, Molenaar J, Lambert P H., Proesmans W, van Munster P. The complement system in hemolytic-uremic syndrome in childhood. Clin Nephrol 1980 13 (4) 168-171
13. Thurman J M., Marians R, Emlen W et al. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009 4 (12) 1920-1924
14. Markiewski M M., Lambris J D. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol 2007 171 (3) 715-727
15. van Setten P A., van Hinsbergh V W., van den Heuvel L P. et al. Monocyte chemoattractant protein-1 and interleukin-8 levels in urine and serum of patents with hemolytic uremic syndrome. Pediatr Res 1998 43 (6) 759-767
16. Lathem W W., Grys T E., Witowski S E. et al. StcE, a metalloprotease secreted by Escherichia coli O157:H7, specifically cleaves C1 esterase inhibitor. Mol Microbiol 2002 45 (2) 277-288
17. Grys T E., Walters L L., Welch R A. Characterization of the StcE protease activity of Escherichia coli O157:H7. J Bacteriol 2006 188 (13) 4646-4653
18. Lathem W W., Bergsbaken T, Welch R A. Potentiation of C1 esterase inhibitor by StcE, a metalloprotease secreted by Escherichia coli O157:H7. J Exp Med 2004 199 (8) 1077-1087
19. Giannakis E, Jokiranta T S., Male D A. et al. A common site within factor H SCR 7 responsible for binding heparin, C-reactive protein and streptococcal M protein. Eur J Immunol 2003 33 (4) 962-969
20. Sánchez-Corral P, Pérez-Caballero D, Huarte O et al. Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome. Am J Hum Genet 2002 71 (6) 1285-1295
21. Martinez-Barricarte R, Pianetti G, Gautard R et al, European Working Party on the Genetics of HUS. The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2008 19 (3) 639-646
22. Paixo-Cavalcante D, Botto M, Cook H T., Pickering M C. Shiga toxin-2 results in renal tubular injury but not thrombotic microangiopathy in heterozygous factor H-deficient mice. Clin Exp Immunol 2009 155 (2) 339-347
23. Ikeda K, Nagasawa K, Horiuchi T, Tsuru T, Nishizaka H, Niho Y. C5a induces tissue factor activity on endothelial cells. Thromb Haemost 1997 77 (2) 394-398
24. Wojta J, Huber K, Valent P. New aspects in thrombotic research: complement induced switch in mast cells from a profibrinolytic to a prothrombotic phenotype. Pathophysiol Haemost Thromb 2003 33 (5-6) 438-441